ArticleDiscover oncology2026
Identification of the disulfidptosis-related gene G6PD as a potential biomarker and therapeutic target in pancreatic ductal adenocarcinoma by integrative bioinformatics analysis and experimental validation.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic adenocarcinoma (PAAD) is a highly lethal digestive system tumor with a low five-year survival rate and limited treatment efficacy, underscoring the need for new therapeutic targets. Disulfidptosis, a novel cell death mechanism, shows promise for tumor therapy. Glucose-6-phosphate dehydrogenase (G6PD), a key gene in disulfidptosis, regulates antioxidant defense, biosynthesis, and metabolism. This study investigates G6PD’s role in PAAD and its therapeutic potential via bioinformatics and in vitro experiments.
methodsWe analyzed the expression of G6PD in PAAD and its correlation with clinical characteristics using data matrices from multiple public databases. At the same time, we evaluated the correlation of G6PD expression with the immune microenvironment and immunotherapy. Finally, GO/KEGG enrichment analysis identified the biological processes related to G6PD, and in vitro experiments preliminarily identified the potential of G6PD as an activation target for disulfidptosis in PAAD.
resultsG6PD is overexpressed in PAAD and correlates with clinical stage, histological grade, and prognosis. It shows positive associations with immune cell types, regulatory genes, MHC molecules, and chemokines, suggesting that G6PD expression was associated with immune cell infiltration scores and immunomodulatory signatures in PAAD. GO/KEGG analysis linked G6PD to the pentose phosphate pathway, glutathione, and NADPH metabolism, highlighting its role in redox homeostasis and metabolic reprogramming. The G6PD inhibitor RRx-001 induces disulfidptosis-like features in the PAAD cell line SW1990 by reducing NADPH generation, suppressing cystine uptake, and promoting F-actin contraction and aggregation.
conclusionsOur study reveals the critical role of G6PD in PAAD. High G6PD expression is closely associated with unfavorable clinicopathological features and poor prognosis in PAAD patients, as well as with specific tumor immune microenvironment characteristics. The G6PD inhibitor RRx-001 can induce disulfidptosis-like features in PAAD cells, demonstrating the potential of G6PD as a therapeutic target and providing new ideas for the precise treatment of PAAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.